BCL2L1 and Thrombocytopenia: Although navitoclax has progressed to clinical trials and there have been initial signs of efficacy in some cancers, navitoclax also produced dose dependent thrombocytopenia by antagonizing the survival function of Bcl-XL in platelets [16].